Holen Sie sich die Stockscreener-App
8.91
3.97%
0.34
Vorhandelsmarkt:
8.87
-0.04
-0.45%
Schlusskurs vom Vortag:
$8.57
Offen:
$9.14
24-Stunden-Volumen:
768.67K
Relative Volume:
0.88
Marktkapitalisierung:
$471.83M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.56M
KGV:
-11.33
EPS:
-0.7861
Netto-Cashflow:
$-15.45M
1W Leistung:
-5.81%
1M Leistung:
+1.83%
6M Leistung:
+336.76%
1J Leistung:
+381.62%
1-Tages-Spanne:
$8.72
$9.35
1-Wochen-Bereich:
$8.25
$10.09
52-Wochen-Spanne:
$1.34
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.91 | 471.83M | 0 | -23.56M | -15.45M | -0.7861 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-09 | Eingeleitet | Mizuho | Outperform |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Immix Biopharma (NASDAQ:IMMX) Now Covered by Morgan Stanley - Defense World
Immix Biopharma, Inc. Files Form 8-K Announcing Amendment to ATM Agreement and Legal Opinion – March 25, 2026 - Minichart
Millennium Management LLC Acquires Significant Stake in Immix Biopharma Inc - GuruFocus
Immix Biopharma, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma amends at-the-market offering agreement for up to $100 million - Investing.com
Immix Biopharma Amends ATM Offering to Raise Capital - TipRanks
Immix Biopharma Updates $100 Million ATM Equity Offering With Citizens JMP Securities - TradingView
Immix Biopharma 2025 10-K: Net loss $29.44M, EPS $(0.89) - TradingView
Immix Biopharma (NASDAQ: IMMX) amends $100M at-the-market stock sale - Stock Titan
Immix Biopharma (IMMX) plans $100M ATM with Citizens JMP Securities - Stock Titan
Immix Biopharma (NASDAQ: IMMX) advances NXC-201 with designations and $100M offering - Stock Titan
Immix stock wins Morgan Stanley bullish view (IMMX:NASDAQ) - Seeking Alpha
Immix Biopharma (NASDAQ:IMMX) Now Covered by Analysts at Morgan Stanley - MarketBeat
Morgan Stanley initiates Immix Biopharma stock with overweight rating By Investing.com - Investing.com Canada
Immix Biopharma signed Amendment No. 1 to its ATM (At-the-Market) Offering Agreement on March 25, 2026. - Bitget
Targets Report: Does Immix Biopharma Inc have consistent dividend growth2026 Sector Moves & Intraday High Probability Setup Alerts - baoquankhu1.vn
Artificial Intelligence Technology Solutions, Inc.: AITX's RAD and Immix Announce Integration of RAD Devices into Immix Platform - FinanzNachrichten.de
If You Invested $1,000 in Immix Biopharma Inc (IMMX) - Stock Titan
Market Wrap: Is Immix Biopharma Inc stock a buy or sell2026 Spike Watch & Daily Price Action Insights - baoquankhu1.vn
Millennium Group and Israel Englander disclose 2.81M IMMX stake (IMMX) - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Shares Down 8.9%Should You Sell? - MarketBeat
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3%What's Next? - MarketBeat
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Drops By 13.4% - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Hits New 12-Month HighHere's Why - MarketBeat
Immix Biopharma (IMMX) to Release Earnings on Monday - MarketBeat
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch - MSN
Immix Biopharma (NASDAQ:IMMX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $15.00 - Defense World
IMMX Technical Analysis & ETF Price Forecast - Intellectia AI
Immix Biopharma (NASDAQ:IMMX) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Citizens initiates Immix Biopharma stock coverage with outperform rating By Investing.com - Investing.com Canada
Citizens initiates Immix Biopharma stock coverage with outperform rating - Investing.com South Africa
Aug Wrap: Does Immix Biopharma Inc have consistent dividend growthMarket Growth Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Macro Review: Is Immix Biopharma Inc stock a good pick for beginners2026 Market Overview & Growth Focused Entry Point Reports - baoquankhu1.vn
Why Immix Biopharma Inc. stock could rally in 20262026 Big Picture & Reliable Trade Execution Plans - Naître et grandir
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
33,035,515 Common Stock of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 8-MAR-2026. - marketscreener.com
Is Immix Biopharma Inc. stock a top momentum play2025 Big Picture & Detailed Earnings Play Strategies - Naître et grandir
Trade Recap: Is Immix Biopharma Inc in a bullish channel2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Insider Buy: What dividend growth rate does Immix Biopharma Inc offerTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
IMMX Should I Buy - Intellectia AI
IMMX Technical Analysis & Stock Price Forecast - Intellectia AI
IMMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment manager Saturn V holds 6.97% of Immix Biopharma (IMMX) - Stock Titan
Immix Biopharma (IMMX) sees Janus Henderson report 7.4% stake - Stock Titan
Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):